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Abstract	
Radiotherapy	is	a	life-saving	treatment	for	head	and	neck	cancers,	but	almost	100%	of	patients	develop	
dry	 mouth	 (xerostomia)	 because	 of	 radiation-induced	 damage	 to	 their	 salivary	 glands.	 Patients	 with	
xerostomia	suffer	 symptoms	 that	 severely	affect	 their	health	as	well	as	physical,	 social	and	emotional	
aspects	of	 their	 life.	The	current	management	of	 xerostomia	 is	 the	application	of	 saliva	 substitutes	or	
systemic	 delivery	 of	 saliva-stimulating	 cholinergic	 agents,	 including	 pilocarpine,	 cevimeline	 or	
bethanechol	 tablets.	 It	 is	 almost	 impossible	 for	 substitutes	 to	 replicate	 all	 the	 functional	 and	 sensory	
facets	of	natural	saliva.	Salivary	stimulants	are	a	better	treatment	option	than	saliva	substitutes	as	the	
former	 induce	 the	 secretion	 of	 natural	 saliva	 from	 undamaged	 glands;	 typically,	 these	 are	 the	minor	
salivary	 glands.	 However,	 patients	 taking	 cholinergic	 agents	 systemically	 experience	 pharmacology-
related	side	effects	including	sweating,	excessive	lacrimation	and	gastrointestinal	tract	distresses.	Local	
delivery	 direct	 to	 the	 buccal	 mucosa	 has	 the	 potential	 to	 provide	 rapid	 onset	 of	 drug	 action,	 i.e.	
activation	of	minor	salivary	glands	within	the	buccal	mucosa,	while	sparing	systemic	drug	exposure	and	
off-target	 effects.	 This	 critical	 review	 of	 the	 technologies	 for	 the	 local	 delivery	 of	 saliva-stimulating	
agents	includes	oral	disintegrating	tablets	(ODTs),	oral	disintegrating	films,	medicated	chewing	gums	and	
implantable	drug	delivery	devices.	Our	analysis	makes	a	strong	case	for	the	development	of	ODTs	for	the	
buccal	 delivery	 of	 cholinergic	 agents:	 these	must	 be	 patient-friendly	 delivery	 platforms	 with	 variable	
loading	capacities	that	release	the	drug	rapidly	 in	fluid	volumes	typical	of	residual	saliva	 in	xerostomia	
(0.05	to	0.1	mL).	 
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Radiation-induced	xerostomia,	saliva,	salivation,	salivary	substitutes,	salivary	stimulants,	orally	
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1 Introduction	
	
1.1  Radiation-induced xerostomia (dry mouth) 
Head	and	neck	cancer	 is	a	general	 term	that	 includes	cancers	of	oral	cavity,	pharynx,	nasal	cavity	and	
larynx.	In	the	UK,	the	average	national	incidence	of	the	head	and	neck	cancer	was	19.2	per	100,000	of	
the	population	(Cancer	Research	UK	A),	and	the	majority	of	this	population	is	diagnosed	with	head	and	
neck	 cancer	 at	 the	 age	 of	 60	 to	 69	 years	 old	 (Cancer	 Research	 UK	 B).	 The	 most	 commonly	 used	
treatments	 for	 patients	with	 head	 and	 neck	 cancers	 are	 radiotherapy,	 chemotherapy,	 and	 surgery	 or	
combination	of	these	approaches.	Salivary	gland	damage	occurs	in	95%	to	100%	of	patients	treated	with	
radiotherapy,	which	leads	to	the	development	of	xerostomia	(Chambers	et	al.,	2004).	Xerostomia	is	the	
subjective	 feeling	of	dry	mouth	which	may	exist	as	a	consequence	of	 reduced	salivary	 flow	(Cassolato	
and	Turnbull,	2003).	Head	and	Neck	cancer	patients	not	only	suffer	from	oral	distress	but	other	clinical	
complications	 such	 as	 malnutrition,	 dental	 problems,	 and	 depression,	 not	 surprisingly,	 all	 of	 these	
compromise	the	quality	of	the	patient’s	life	(Chambers	et	al.,	2004).		
This	 review	 aims	 to	 investigate	 whether	 improvements	 to	 the	 formulations	 currently	 used	 to	 treat	
radiation-induced	 xerostomia	 are	 possible.	 The	 review	 critically	 evaluates	 the	 current	 options	 for	 the	
treatment	 of	 radiation-induced	 xerostomia	 and	 advocates	 local	 administration	 of	 saliva-stimulating	
agents	to	the	buccal	region.	Our	evaluation	recognises	that	any	product	for	delivering	drugs	to	stimulate	
the	 secretion	 of	 saliva	 should	 be	 designed	 in	 accordance	 with	 the	 principles	 of	 patient-centred	
medicines,	i.e.	with	patient	requirements	at	the	core	of	the	design.		
	
1.2  Sal iva and sal ivation 
Saliva	 is	 a	 very	 complex	 fluid;	 water	 forms	 the	 main	 fraction	 combined	 with	 electrolytes,	 minerals,	
buffers,	growth	factors,	enzymes,	cytokines,	proteins,	and	immunoglobulins	(Amerongen	and	Veerman,	
2002).	 These	 components	 are	 vital	 in	 maintaining	 oral	 homoeostasis	 that	 includes	 good	 oral	 health,	
mastication,	 digestion,	 regulation	 of	 oral	 flora,	 speech	 and	 oral	 cleansing	 (Amerongen	 and	 Veerman,	
2002).	Saliva	is	produced	by	the	major	and	the	minor	salivary	glands.	The	major	salivary	glands	are	pairs	
of	parotid,	sublingual	and	submandibular	salivary	glands	(fig	1).			
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Figure	1:	Illustration	of	salivary	glands	types	and	position.		
	
The	minor	 salivary	 glands	 are	 600	 to	 1000	 glands	 distributed	 throughout	 the	 oral	 cavity,	 in	 the	 sub-
mucosal	 layer	 beneath	 the	 oral	 mucosal	 surface,	 with	 greatest	 density	 in	 the	 buccal	 cavity	 and	 lips	
(Dodds	et	al.,	2005;	Wang	et	al.,	2015).	Although	90%	of	the	average	daily	salivary	secretion,	1	to	1.5	L,	is	
produced	by	major	salivary	glands,	the	minor	salivary	glands	spontaneously	produce	around	10%	of	the	
total	 average	 of	 salivary	 secretions	 (Sonesson	 et	 al.,	 2003).	 Minor	 salivary	 glands	 produce	 salivary	
secretion	that	is	rich	with	mucin	protein	which	protects	the	oral	mucosa	from	dryness	(Sonesson	et	al.,	
2003).	For	the	major	salivary	glands,	the	unstimulated	salivary	flow	average	is	0.3	mL/min	(Amerongen	
and	 Veerman,	 2002),	whereas,	 the	 stimulated	 salivary	 flow	 rate	 is	 between	 1	 to	 2	mL/min	 (Sreebny,	
2000).	The	lowest	salivary	flow	rate	is	during	sleeping,	(0.1	mL/min),	and	the	maximum	flow	rates,	4	to	5	
mL/min,	are	observed	during	mastication	or	stimulation	(Porter	et	al.,	2004).	The	minor	salivary	glands’	
flow	rate	varies	according	to	the	anatomical	location.	For	example,	in	a	study	of	300	healthy	subjects	the	
mean	saliva	flow	rates	were	2.10	±	0.66	µL/min/cm2	(lower	labial	glands),	2.14	±	0.62	µL/min/cm2	(upper	
labial	 glands),	 2.88	 ±	 0.72	 µL/min/cm2	 (buccal	 glands)	 and	 2.15	 ±	 0.51	 µL/min/cm2	 (palatal	 glands),	
respectively	(Wang	et	al.,	2015).	The	flow	rate	of	buccal	glands	was	significantly	higher	than	the	rates	of	
other	locations	(P<0.01)	(Wang	et	al.,	2015).		
	
The	microanatomy	of	both	types	of	salivary	glands	is	similar.	Salivary	gland	cells	are	mainly	acinar	cells,	
various	duct	 systems	cell,	 and	myoepithelial	 cells.	 In	general,	acinar	cells	determine	 the	 type	of	 saliva	
secreted	by	different	glands	(Holsinger	and	Bui,	2007).	Parotid	glands	produce	the	serous	type	of	saliva	
while	 the	mucous	type	of	saliva	 is	produced	by	the	minor	salivary	glands	and	by	the	sublingual	gland.	
The	mixed	type	of	saliva	(serous	and	mucous)	 is	generated	by	the	submandibular	salivary	glands.	Duct	
system	 cells	 act	 as	 a	 network	 to	 transport	 saliva	 from	 site	 of	 production	 to	 the	 oral	 cavity,	 and	
myoepithelial	cells	help	in	the	saliva	secretion	proses	(Holsinger	and	Bui,	2007).	
	
Salivation	is	induced	under	the	control	of	sympathetic	and	parasympathetic	nervous	system.	The	major	
salivary	 glands	 are	 innervated	 by	 both	 sympathetic	 and	 parasympathetic	 nervous	 system	 stimulants,	
while	 the	 minor	 salivary	 glands	 are	 supplied	 with	 little	 or	 no	 sympathetic	 innervations	 (Proctor	 and	
Carpenter,	 2007).	 Salivary	 production	 is	 mediated	 through	 the	 binding	 of	 sympathetic	 and	
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parasympathetic	 neurotransmitters	 to	 their	 receptors.	 Acetylcholine	 is	 the	 parasympathetic	
neurotransmitter	 that	 binds	 to	 five	 subtypes	 the	muscarinic	 receptors,	M1-M5	 (Gautam	et	 al.,	 2004).	
Knockout	gene	experiments	using	mutant	mice	revealed	that	M1	and	M3	control	of	salivary	secretion	
(Gautam	 et	 al.,	 2004).	 The	 sympathetic	 nervous	 system	 activation	 is	mediated	 by	 the	 binding	 of	 the	
sympathetic	neurotransmitter,	adrenaline,	 to	alpha1-	and	beta1-	adrenoceptors,	on	the	surface	of	 the	
acinar	cells	(Proctor	and	Carpenter,	2007).		
	
1.3  Radiation-induced xerostomia 
The	 standard	 treatment	 plan	 for	 patients	 diagnosed	 with	 head	 or	 neck	 cancer	 is	 radiation	 therapy	
usually	combined	with	surgery	and/or	chemotherapy	(Yom,	2015).	The	major	salivary	glands	are	more	
externally	 located	 with	 respect	 to	 most	 of	 the	 tumours	 attributed	 to	 head	 and	 neck	 cancer	 and	
therefore	 are	 usually	 present	 in	 the	 fields	 of	 radiation	 exposure	 (Vissink	 et	 al.,	 2015a).	 Different	
treatment	 procedures	 are	 available	 to	 treat	 patients	 with	 head	 and	 neck	 cancer.	 Conventional	
radiotherapy	 (RT)	 and	 intensity-modulated	 radiotherapy	 (IMRT)	 are	 among	 these	 strategies,	 and	 they	
affect	salivary	glands’	hypofunction	and	thus	affect	the	prevalence	of	xerostomia.	Several	studies	have	
shown	that	salivary	function	and	salivary	flow	rate	are	better	preserved	when	using	 IMRT	(Tribius	and	
Bergelt,	 2011).	 For	 example,	 patients	 reported	 less	 severe	 xerostomia	 when	 treated	 with	 IMRT	 in	
comparison	to	conventional	RT	(Michael	et	al.,	2007).	The	severity	of	xerostomia	was	39.3%	vs	82.1%;	P	
=	0.001,	with	higher	stimulated	parotid	flow	rate	(0.90	mL/min	v	0.05	mL/min;	P	=	0.0001),	and	higher	
stimulated	 whole	 salivary	 flow	 rate	 (0.41	 mL/min	 v	 0.20	 mL/min;	 P	 =	 0.001)	 (Michael	 et	 al.,	 2007).	
Standardisation	of	the	total	amount	of	IMRT	dose	fractionation	for	head	and	neck	cancer	is	difficult,	as	
this	depends	on	the	extent	of	the	patient’s	tumour.	However,	a	typical	plan	 is	to	treat	patients	with	a	
total	 amount	 of	 radiotherapy	 between	 50	 to	 70	 gray	 (Gy).	 This	 is	 achieved	 by	 a	 daily	 fraction,	 for	
example	 2	 Gy,	 over	 a	 period	 of	 many	 weeks	 (Kean	 et	 al.,	 2009).	 Common	 changes	 observed	 in	 the	
salivary	glands	after	irradiation	treatment	are	degranulation	and	necrosis	of	the	acinar	cells	due	to	their	
membrane	damage,	as	well	as	chronic	 inflammation	and	fibrosis	of	the	gland	lobules,	especially	 in	the	
periductal	 and	 intraocular	 areas	 (Grundmann	 et	 al.,	 2009;	 Konings	 et	 al.,	 2005).	 As	 a	 result,	 a	 rapid	
decrease	of	up	to	50-60%	in	the	salivary	function	in	the	initial	phase	of	treatment,	if	the	radiation	passes	
through	 the	 major	 salivary	 glands	 (parotid,	 sublingual	 and	 submandibular).	 Upon	 completion	 of	 the	
treatment,	 	saliva	usually	falls	to	its	minimum	flow	rate	(Chambers	et	al.,	2004).	 In	healthy	individuals,	
the	 stimulated	 and	 the	 unstimulated	 salivary	 flow	 averages	 are	 1	 to	 2	 mL/min	 and	 0.3	 mL/min,	
respectively	(Amerongen	and	Veerman,	2002;	Sreebny,	2000).	In	contrast,	individuals	are	considered	to	
have	xerostomia	when	the	unstimulated	flow	rates	are	less	than	0.1	mL/min	and	when	the	stimulated	
salivary	flow	rates	are	less	than	0.5	mL/min	(Humphrey	and	Williamson,	2001).	
	
Studies	of	radiation-induced	xerostomia	that	consider	the	impact	of	radiation	on	minor	salivary	glands	
are	 scarce	 (Pinna	 et	 al.,	 2015).	 However,	 in	 comparison	 to	 major	 salivary	 glands,	 the	 minor	 salivary	
glands	are	 less	sensitive	to	radiation	since	serous	cells	are	more	susceptible	to	radiation	damage	than	
the	mucous	cells	 (Van	de	Water	et	al.,	2009).	Additionally,	minor	salivary	glands	are	higher	 in	number	
and	are	more	widely	distributed	(Dodds	et	al.,	2005).		
	
Radiotherapy	not	only	reduces	salivary	flow	but	it	also	induces	changes	in	the	chemical	composition	of	
the	saliva.	Studies	have	shown	a	statistically	significant	change	 in	 the	saliva	electrolyte	concentrations	
during	 the	development	of	 radiation-induced	xerostomia.	For	example,	 there	are	noted	concentration	
increases	in	sodium,	calcium,	magnesium	and	chloride	ion	(table	1)	which	are	all	dependent	on	salivary	
flow	rate	(Pinna	et	al.,	2015).	Radiation	treatment	also	contributes	to	a	decrease	 in	saliva	bicarbonate	
concentration,	and	 this	affects	buffer	 capacity.	These	changes	are	 related	 to	damage	 to	 the	 secretory	
5	
	
units	and	tubules	of	 the	salivary	glands.	As	a	 result	 these	alterations	and	 in	addition	to	a	 reduction	 in	
water	content,	the	saliva	becomes	very	viscous	and	acidic	with	a	change	in	pH	from	7	to	5	(Pinna	et	al.,	
2015).	
	
Table	 1:	 The	 concentration	 of	 saliva	 components	 before	 and	 after	 radiation	 treatment.	 Table	 adapted	 from	 (Dreizen	 et	 al.,	
1976),	a	study	carried	out	with	samples	of	stimulated	whole	saliva	of	30	patients	with	head	or	neck	tumours.	This	table	also	
includes	the	result	of	the	analysis	of	39	patients	who	were	diagnosed	with	nasopharyngeal	carcinoma,	(Pow	et	al.,	2016).	Data	
collection	 points	 were	 every	 3,	 6	 and	 12	 months.	 The	 table	 illustrates	 the	 six	 months’	 data	 average.	 Based	 on	 the	
concentrations	of	the	saliva	components	listed	below,	the	estimated	salivary	ionic	strength	before	and	after	radiotherapy	is	88	
mmol	 and	 148	 mmol	 respectively.	 P	 or	 probability	 level	 of	 less	 than	 0.001	 indicates	 statistically	 significant	 changes	 in	 the	
measurements.	
Saliva components Before Radiotherapy (mEq/L) After Radiotherapy 
(mEq/L) 
P value 
Sodium (Na +)  38.42	 78.27	 <0.001	
Calc ium (Ca 2+)  1.51	 2.80	 >0.05	
Magnesium (Mg 2+)  0.37	 0.99	 <	0.001	
Chloride (Cl  -)  24.68	 45.03	 <	0.001	
Bicarbonate (HCO 3 
-)  19.80	 7.95	 <	0.001	
Nitrate (NO 3 
-)  0.21	 0.06	 0.015	
Sulphate (SO 4 
2-)  0.10	 0.22	 <	0.001	
Lactate (C 3H 6O 3 
-)  0.01	 0.15	 <	0.001	
Formate (CHO 2 
-)  0.01	 0.04	 0.011	
Propionate (C 3H 6O 2 
-)  0.05	 0.06	 Unknown	
Acetate (C 2H 3O 2 
-)  0.54	 0.59	 Unknown	
Thiocyanate (SCN -)  0.30	 0.06	 <	0.001	
	
1.4  Impact of xerostomia on health and quality of l i fe 
Abnormalities	which	affect	 the	quality	or	quantity	of	saliva	will	diminish	the	quality	of	 life	of	patients.	
The	quality	 of	 life	 is	 defined	 as	 “the	 assessment	 of	 an	 individual’s	well-being,	 including	 all	 emotional,	
social	and	physical	aspects”	 (Dirix	et	al.,	2008).	Oral	 cavity	dryness,	 inflammations,	and	ulcers	 start	 to	
appear	 at	 the	 early	 stages	 of	 xerostomia,	which	 translates	 into	 difficulties	 in	 speech	 and	 swallowing.	
Difficulties	 in	speaking	affect	patients’	ability	 to	communicate	and	work.	Moreover,	any	change	 in	 the	
saliva	quality	will	 lead	to	a	reduction	 in	the	number	of	taste	buds	(Henkin	et	al.,	1972).	Thus,	patients	
with	xerostomia	will	experience	a	reduction	of	nutritional	intake	that	will	lead	to	significant	weight	loss	
in	 many	 patients	 (Chencharick	 and	 Mossman,	 1983).	 Microbial	 infections	 and	 dental	 caries	 develop	
because	of	the	loss	of	antimicrobial	and	antifungal	properties	of	saliva	(Gurkar	et	al.,	2016).	Reduction	in	
saliva	production	causes	a	thirstiness	sensation	that	affects	the	patient’s	sleep	patterns	as	they	need	to	
moisturise	the	mouth	constantly.	To	alleviate	the	symptoms,	patient’s	take	regular	sips	of	liquid	which	
results	 in	 the	 significant	 production	 of	 urine	 that	 further	 disturb	 sleep	 patterns.	 Thus,	 the	 impact	 of	
radiation-induced	xerostomia	on	a	patients’	health	and	quality	of	life	must	be	taken	into	consideration	
when	designing	better	therapeutic	products	to	treat	this	condition	(section	4,	page	16).		
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2 Current	treatments	for	xerostomia	
Commercially	available	treatments	of	radiation-induced	xerostomia	aim	to	elevate	dry	mouth	symptoms	
by	either	using	 salivary	 substitutes	when	 salivary	 glands	 are	 completely	 damaged	or	by	using	 salivary	
stimulants	when	there	is	residual	salivary	gland	function.	
	
2.1   Sal ivary substitutes 
Salivary	substitutes,	for	example,	water,	milk	and	artificial	saliva,	are	used	to	provide	lubrication	and	to	
moisturise	the	oral	cavity	surface	and	therefore	relieve	the	sensation	of	dryness.	 It	has	been	reported	
that	 frequent	 sips	 of	 water	 are	 effective	 in	 dry	 mouth	 management.	 Moreover,	 using	 milk	 was	 also	
found	 to	 be	 beneficial	 as	 it	 contains	 chemical	 constituents	 that	 contribute	 towards	 lubrication,	
moisturising	 and	 buffering	 oral	 acid	 (Herod,	 1994).	 Artificial	 saliva	 is	 the	 term	 given	 to	 commercial	
products	that	contain	specific	ingredients	that	mimic	one	or	more	of	the	properties	of	the	natural	saliva	
(table	2).	Salivary	substitutes	are	available	in	different	dosage	forms	such	as	liquids,	sprays	and	lozenges	
(table	2,	BNF,	2016).	Patients’	selection	of	salivary	substitutes	is	based	on	lubrication	effect,	duration	of	
action,	 taste,	 delivery	 system	 and	 price	 of	 the	 product.	 The	 first	 generation	 of	 artificial	 liquid	 saliva	
substitutes	 were	 aqueous	 solutions	 of	 carboxymethylcellulose	 (CMC),	 mineral	 salts,	 fluoride,	
sweeteners,	and	preservatives	that	mimicked	the	actual	saliva	composition	(Temmel	et	al.,	2005).	Mucin	
is	a	natural	salivary	protein	which	is	responsible	for	protecting	the	oral	mucosa	from	dryness.	Therefore,	
the	second	generation	of	artificial	saliva	included	mucin	as	an	ingredient,	and	these	were	well	tolerated	
by	patients	(Davies,	2000).	
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Table	2:	Examples	of	currently	available	salivary	substitutes	that	can	be	prescribed	in	the	UK	for	radiation-induced	xerostomia	
Product	name	
(Manufacturer)	
Formulation	 Composition	 Application	
(when	
required)	
AS	Saliva	Orthana®	
(AS	Pharma)	
	
	
	
Oral	spray	
50	mL	
Gastric	mucin	3.5%	w/v,	xylitol	2%	w/v,	
sodium	fluoride	4.2	mg/L,	as	well	as	
preservatives	and	flavoring	agents.	pH	
neutral,	aqueous	base	formulation.	
Spray	onto	oral	
and	pharyngeal	
mucosa	2-3	
times.	
30-lozenge	
pack	
Mucin	65	mg,	xylitol	59	mg	in	a	sorbitol	
basis,	pH	neutral.	
Dissolve	
lozenge	in	the	
mouth.	
Biotène	Oralbalance®	
(GSK)	
	
Mouth	Gel	
50g	
Lactoperoxidase,	Lactoferrin,	lysozyme,	
glucose	oxidase	and	xylitol	in	a	gel	basis,	
alcohol-free.	
Apply	directly	
to	gingivae	or	
tongue.	
BioXtra®	(RIS	products)	
	
Mouth	Gel	
40	mL	
Lactoperoxidase,	Lactoferrin,	Lysozyme,	
whey	colostrum,	xylitol	and	other	
ingredients.	Alcohol-free,	aqueous	base	
formulation.	
Mouth	gel	
application	
when	required.	
Glandosane	®	
(Fresenius	Kabi)	
	
Aerosol	
spray	50	mL	
Carmellose	sodium	500	mg,	sorbitol	1.5	
g,	KCl	60	mg,	NaCl	42.2	mg,	MgCl2	2.6	
mg,	CaCl2	7.3	mg	and	K2HPO4	
17.1	mg/50	g,	pH	5.7,	suspension.	
Spray	onto	the	
oral	and	
pharyngeal	
mucosa	for	1-2	
seconds	as	
often	as	
required.	
Aquoral®	
(Sinclair	IS)	
	
Oral	Spray	
40	mL	
Contains	oxidised	glycerol	triesters,	
silicon	dioxide	and	flavoring	agent	
Include	aspartame,	suspension.	
One	application	
to	the	buccal	
pouch,	3-4	
times	a	day.	
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Owing	 to	 the	biochemical	 complexity	of	 natural	 saliva	 (fig	 2),	 no	 salivary	 substitute	 can	match	 all	 the	
physio-chemical	 parameters	 of	 it	 (Samarawickrama,	 2002).	 Furthermore,	 the	 efficacy	 of	 a	 saliva	
substitute	is	also	dependent	on	the	guidance	that	is	given	to	the	patient,	e.g.	when	to	apply	and	what	
product	to	use.	The	manufacturer	provides	instructions	for	the	use	of	each	artificial	saliva	product	and	
non-compliance	 with	 these	 instructions	 reduces	 the	 effectiveness	 of	 the	 salivary	 substitute.	 Patients	
should	use	different	products	based	on	the	severity	of	xerostomia	and	the	time	of	the	day.	For	example,	
in	 severe	 xerostomia,	 a	 gel-like	 salivary	 substitute	 should	 be	 used	 overnight,	 whereas	 a	 more	 liquid	
substitute	may	 be	more	 appropriate	 during	 the	 day	 (Regelink	 et	 al.,	 1989).	 Saliva	 substitutes	 have	 a	
short	 duration	 of	 action	 and	 therefore	 require	 frequent	 re-application,	 which	 creates	 issues	 around	
patient	adherence	and	increases	the	cost	of	therapy	(Jensen	et	al.,	2010).	Therefore,	the	stimulation	of	
natural	saliva	by	the	use	of	salivary	stimulant	agents	may	offer	a	better	treatment	option	compared	to	
salivary	substitutes.		
	
	
	
Figure	2:	Examples	of	salivary	constituents	and	functions.	
	 	
Digestion	
•  Amylase	
•  Protease	
•  Lipase	
•  DNAse	
•  RNAse	
Anti-bacterial	
•  Lysozyme	
•  Lactoferrin	
•  Histatins	
•  Cystatins	
		Bolus-formation		
•  Zinc	
•  Mucins	
•  Water	
•  Carbonic	
anhydrase	
Lubrication	
•  Statherin	
•  Calcium	
•  Phosphate	
•  Mucins	
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2.2  Sal ivary st imulants  
Cholinergic	 agents	 act	 through	 the	 parasympathetic	 nervous	 system	 and	 have	 been	 developed	 as	
salivary	stimulants	for	xerostomia.	These	drugs,	which	include	pilocarpine,	cevimeline,	and	bethanechol,	
induce	 the	 secretion	 of	 natural	 saliva	 from	 the	 undamaged	 part	 of	 the	 salivary	 glands	 through	 their	
action	on	muscarinic	receptors	(Holmes,	1998;	Napeñas	et	al.,	2009).	
	
Salagen®	 (a	 pilocarpine	 HCl	 tablet)	 is	 the	 only	 drug	 product	 for	 the	 treatment	 of	 radiation-induced	
xerostomia	that	has	been	approved	in	Europe	and	the	USA.		It	is	a	film-coated	tablet	that	contains	5	mg	
of	 pilocarpine	 HCl,	microcrystalline	 cellulose	 as	 a	 binder,	 stearic	 acid	 as	 a	 lubricant	 and	 acidifier	 and	
carnauba	wax	as	a	polishing	agent.	Pilocarpine	is	effective	not	only	in	radiation-induced	xerostomia	but	
also	 in	 diseases	 of	 the	 salivary	 glands	 such	 as	 Sjögren’s	 syndrome.	 Significant	 improvements	 to	 the	
symptoms	of	xerostomia	can	be	achieved	by	administering	5	mg	pilocarpine	 three	 times	a	day	over	a	
period	 of	 8	 to	 12	weeks	 (DuRant	 et	 al.,	 1993).	 The	maximum	prescribed	 dose	 of	 30	mg	 daily	 can	 be	
considered	for	patients	who	have	not	responded	to	the	fixed	dose	of	5	mg	three	times	daily	(Vissink	et	
al.,	 2015b).	 Pilocarpine	 can	 also	 be	 used	 as	 a	maintenance	 therapy	 during	more	 extended	 treatment	
periods	(Acobs	et	al.,	1996).	 	Peak	plasma	concentrations	of	15	and	41	µg/L	for	pilocarpine	have	been	
recorded	after	ingestion	of	5	mg	or	10	mg	tablets	three	times	a	day,	with	peak	concentrations	reached	
in	 75	 and	50	min	 after	 administration,	 respectively,	 (Guchelaar	 et	 al.,	 1997).	 Pilocarpine	 is	 eliminated	
mainly	in	the	urine	with	an	elimination	half-life	of	45	and	80	min	for	5	and	10	mg	doses,	respectively.	To	
avoid	rapid	elimination	and	maximise	exposure	at	the	site	of	action,	absorption	of	pilocarpine	into	the	
systemic	 system	 should	 be	 minimised,	 e.g.	 by	 local	 administration	 of	 lower	 doses	 direct	 to	 the	
undamaged	salivary	glands.	Sublingual	formulations	will	not	fulfil	this	design	brief	as	the	mucosa	in	this	
region	 has	 high	 permeability	 and	 a	 generous	 blood	 supply.	 A	 buccal	 product	 that	 disperses	 and	 gels	
across	the	inside	of	the	oral	cavity	after	disintegration	more	closely	meets	the	design	brief.	
	
Bethanechol	 is	a	cholinergic	drug	mainly	used	to	treat	urinary	retention.	 In	comparison	to	pilocarpine,	
few	clinical	trials	have	been	conducted	to	examine	the	effect	of	bethanechol	in	patients	with	radiation-
induced	xerostomia	 (Jham	et	al.,	2007).	However,	 increase	 in	 salivary	 secretions,	and	 improvement	 in	
dry	mouth	symptoms	have	been	reported	(Cotomacio	et	al.,	2017).	 	Cevimeline	 is	a	newer	cholinergic	
agonist	that	works	selectively	on	M3	receptors	of	the	secretory	glands,	avoiding	side-effects	mediated	
by	other	muscarinic	receptor	subtypes.	The	efficacy	and	safety	of	30	mg	cevimeline	three	times	a	day	in	
patients	diagnosed	with	 xerostomia	 as	 a	 consequence	of	 Sjögren’s	 syndrome	has	been	demonstrated	
and	cevimeline	HCl	tablets	have	been	licensed	by	the	FDA	for	this	indication	(Fife	et	al.,	2002).		
	
The	efficacy	of	all	the	cholinergic	agents	described	above	has,	to	varying	extent,	been	tested	in	patients	
with	a	radiation-induced	xerostomia	(Chambers	et	al.,	2004).	 Improvements	in	both	salivary	flow	rates	
and	dry	mouth	sensation	were	reported	upon	using	these	treatments.	However,	pharmacology-related	
side-effects	were	 reported	 in	patients	 receiving	all	of	 these	medications,	 including	 transient	 sweating,	
flushing	or	warmth,	 increased	urinary	frequency,	nasal	secretion,	 lacrimation	and	gastrointestinal	tract	
distress	(Chambers	et	al.,	2004;	Wiseman,	1995).		Formulation	of	these	drugs	for	local	delivery	has	been	
advocated	previously	as	a	means	of	avoiding	the	side	effects	associated	with	oral	administration	(Cooper	
et	 al.,	 2015).	 The	 feasibility	 of	 reformulating	 bethanechol	 has	 been	 investigated	 by	 introducing	 a	
saturated	 solution	 of	 the	 drug	 within	 the	 buccal	 cavity	 for	 a	 fixed	 period	 to	 test	 for	 salivary	 gland	
activation.	The	initial	results	were	encouraging,	but	issues	concerning	the	physical	and	chemical	stability	
of	the	saturated	solutions	must	be	resolved	for	this	apparently	simple	formulation	approach	to	succeed	
(Cotomacio	 et	 al.,	 2017).	 	 Although	 pilocarpine,	 cevimeline	 and	 bethanechol	 are	 all	 candidates	 for	
localised	 salivary	 stimulation	 therapy	 for	 radiation-induced	 xerostomia	 (Mercadante	 et	 al.,	 2017),	
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cevimeline	 is	 licensed	by	 the	FDA	only	 for	 the	 treatment	of	xerostomia	 related	 to	Sjögren’s	syndrome	
and	is	not	available	in	many	countries	(José-Antonio	et	al.,	2016).		In	contrast,	pilocarpine	is	indicated	for	
radiation-induced	 xerostomia	 and	 is	 widely	 available	 in	 most	 countries.	 This	 makes	 pilocarpine	 an	
obvious	 candidate	 for	 proof	 of	 concept	 investigations	 into	 the	 topical	 treatment	 of	 xerostomia,	 with	
more	selective	compounds	such	as	cevimeline	potentially	providing	even	greater	selectivity	should	this	
prove	necessary.	
	
Table	3:	Treatments	of	radiation-induced	xerostomia:	limitations	and	research	needs	for	better	therapeutic	options.	
Therapeutic	
options		
Salivary	stimulants		 Salivary	substitutes		
Products		 Pilocarpine	HCl	tablets		
Bethanechol	chloride	tablets	
Cevimeline	HCl	tablets		
	
		
	
	
AS	Saliva	Orthana®	oral	spray	
Biotène	Oralbalance®	gel	
BioXtra®	gel	
Glandosane	®	spray		
Aquoral®	spray																								
Limitations	 The	 limitations	 are	 due	 to	 the	 systematic	 exposure	 of	 the	 drug	
that	produce	off-target	effects	(side	effects)	via	stimulation	of	the	
parasympathetic	 nervous	 system.	 These	 include	 transient	
sweating,	flushing	or	warmth,	 increased	urinary	frequency,	nasal	
secretion,	lacrimation	and	gastrointestinal	tract	distress.	
Short	 duration	 of	 action	 and	
therefore	 require	 frequent	
administration.	
	
The	 available	 products	 are	
simple	 and	 do	 not	mimic	 the	
complexity	 of	 the	 natural	
saliva.	
	
Research	
needs	
Reformulate	 the	 products	 to	 achieve	 local	 therapeutic	 effect	 by	
local	activation	of	the	minor	salivary	glands.	
Design	 of	 a	 product	 that	
better	 mimics	 natural	 saliva.	
Longer	 acting	 salivary	
substitutes	are	also	required.	
	
A	localised	buccal	delivery	system	for	pilocarpine	may	overcome	the	limitations	associated	with	current	
therapy	(table	3).		Despite	the	efficacy	of	pilocarpine	in	treating	radiation-induced	xerostomia	(table	4),	
its	off-target	cholinergic	effects	limit	its	use.		Participants	in	clinical	trials	invariably	reported	side	effects	
after	 oral	 pilocarpine	 treatment.	 The	 side	 effect	 profile	 reduces	 the	 willingness	 of	 patients	 to	 take	
pilocarpine	and	may	result	 in	treatment	cessation.	 	Furthermore,	the	parasympathomimetic	activity	of	
pilocarpine	leads	to	concerns	regarding	cardiovascular	effects,	although	no	significant	responses	in	the	
heart	rate	or	blood	pressure	have	been	noted.	However,	its	administration	is	contraindicated	in	patients	
suffering	from	hypertension	or	other	cardiovascular	or	gastrointestinal	illnesses	(Gornitsky	et	al.,	2004).		
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Table	4:	Studies	that	investigate	the	efficacy	of	pilocarpine	in	patients	with	radiation-induced	xerostomia.	
Authors		 Study	type	 Duration	 of	 the	
study	
Treatment	 Evaluation	 Outcomes	
Leveque	
et	al.,	
1995	
A	double-
blind	study,	
n=207.	
12	weeks	 Pilocarpine	5	mg,	10	
mg	and	placebo	
treatment	were	
administrated	three	
times	a	day.	
Evaluation	of	xerostomia	
was	based	on	a	visual	
analog	scale	questionnaire.	
The	overall	xerostomia	was	improved	upon	using	
pilocarpine	HCl	tablets	of	5	and	10	mg	dose.	The	
over	oral	condition	was	improved	in	53.5%	of	
patients	on	5mg	pilocarpine,	42.9%	of	patients	on	
10	mg	pilocarpine	and	only	25%	of	patients	on	
placebo,	P-value	of	0.01.		
		
Haddad	
and	
Karimi,	
2002	
A	double-
blind	study,	
n=39.		
Over	the	period	of	
radiation	treatment	
and	extra	three	
months	after	the	
end	of	radiotherapy	
treatment.	
Pilocarpine	5	mg	and	
placebo	were	
administrated	three	
times	daily.	
Evaluation	of	xerostomia	
was	based	on	visual	
analogue	scale	
questionnaire	carried	out	
six	months	after	the	end	of	
radiation	therapy.	
The	pilocarpine	HCl	tablets	are	more	effective	in	
comparison	to	placebo.	Using	a	visual	analogue	
scale	questionnaire,	the	severity	of	subjective	
xerostomia	was	40.5%	and	57%	in	the	pilocarpine	
and	placebo	group	respectively.	(P=	0:02,	95%	
confidence	interval	of	the	difference).	
Valdez	et	
al.,	1993	
A	double-
blind	study,	
n=9.		
12	months	 Pilocarpine	5	mg	or	
placebo	were	
administrated	four	
times	a	day.	
Objective	and	subjective	
assessments	were	carried	
weekly	over	the	first	two	
months	of	the	treatment	
and	repeated	later	at	month	
3,	4,	5,	6	and	12.	
Based	on	the	objective	results	of	the	questioner,	
pilocarpine	group	reported	improvements	in	oral	
dryness.		During	radiation	therapy,	a	reduction	of	
around	450	µL/min	in	a	parotid	gland	flow	rate	
was	recorded	in	patients	taking	a	placebo.	
Whereas,	less	than	200	µL/min	reduction	in	
parotid	flow	rate	was	registered	in	the	group	
taking	pilocarpine	HCl	tablets	(p<0.025).			
Fox	et	al.,	
1991	
Double-
blind	study,	
n=39.		
6	months	 Pilocarpine	5	mg	and	
placebo	were	
administrated	three	
times	daily.	
Xerostomia	evaluation	was	
based	on	the	subjective	and	
objective	improvement	that	
was	assisted	on	monthly	
bases.	
Based	on	the	objective	and	subjective	results,	
pilocarpine	HCl	tablets	were	an	effective	
treatment	for	dry	mouth.	90%	of	the	patients	
experienced	improvement	in	oral	dryness.	
Unstimulated	salivary	flow	rates	of	the	parotid	
and	submandibular	glands	were	increased	from,	
0.003	mL/min	and	0.018	mL/min	to	0.048	mL/min	
and	0.028	mL/min	respectively.		
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3 Design	of	a	topical	drug	delivery	system	for	salivary	stimulants	
Since	 the	 function	 of	 minor	 salivary	 glands	 is	 preserved	 better	 than	 the	 major	 salivary	 glands	 post	
radiation	therapy,	 local	delivery	of	cholinergic	agents	provides	a	means	of	drug	targeting	to	the	saliva-
producing	minor	glands	 located	 just	below	the	oral	epithelium.	Advantages	of	buccal	mucosa	as	a	site	
for	 topical	 drug	 delivery	 include:	 (i)	 a	 robust	 nature,	 this	 oro-mucosa	 has	 short	 recovery	 times	 after	
stress	or	damage	(Gandhi	and	Robinson,	1994);	(ii)	the	absence	of	Langerhans	cells	which	offers	a	high	
level	 of	 tolerance	 to	 potential	 allergens	 (Boddé	 et	 al.,	 1990);	 and	 (iii)	 excellent	 accessibility	 and	 easy	
removal	of	the	system	in	case	of	side	effects	(Lee	et	al.,	2000).	Thus	drug	delivery	via	the	mucosal	tissue	
that	 lines	the	inside	of	the	cheeks,	 is	an	ideal	approach	for	the	localised	delivery	of	salivary	stimulants	
(Zhang	et	al.,	2002).	The	buccal	mucosa	not	only	hosts	many	of	the	mouth’s	minor	salivary	glands,	it	is	
also	a	convenient	route	of	administration	(Zhang	et	al.,	2002)	and	avoids	the	expedited	drug	entry	into	
systemic	 circulation	 	 associated	 with	 sublingual	 administration	 (Narang	 and	 Sharma,	 2011).		
Encouragingly,	 delivery	 of	 pilocarpine	 nitrate	 via	 the	 buccal	 mucosa	 in	 beagle	 dogs	 resulted	 in	 an	
absorption	 rate	of	 72.9	 ±	 53	μg/kg/h	 and	 an	 submandibular	 salivary	 flow	 rates	 of	 up	 to	 0.35	mL/min	
(Weaver	et	al.,	1992).		
	
In	addition	to	biopharmaceutical	considerations,	the	physical,	physiological	and	social	needs	of	patients	
should	 be	 utilised	 in	 the	 design	 of	 a	 pharmaceutical	 drug	 product.	 	 This	 approach	 can	 maximise	
therapeutic	 benefit,	 enhance	 patient	 adherence	 and	 aligns	 with	 the	 current	 paradigms	 for	 the	
development	of	more	patient-centred	medicines	(Stegemann	et	al.,	2016).		
	
3.1  Pharmaceutical  dosage forms and technologies 
A	range	of	pharmaceutical	dosage	forms	and	technologies	may	be	utilised	to	deliver	pilocarpine	to	the	
buccal	 mucosa.	 These	 include	 oral	 disintegrating	 tablets	 (ODTs),	 oral	 disintegrating	 films	 (ODFs),	
chewable	gums	and	 implantable	drug	delivery	devices.	All	dosage	 forms	containing	pilocarpine	should	
disintegrate	rapidly	and	completely	in	a	limited	amount	of	saliva	without	the	need	for	water;	e.g.	in	the	
0.05	to	0.1	mL	of	saliva	typically	present	in	patients	with	radiation-induced	xerostomia	(Cho	et	al.,	2010).	
The	formulation	should	also	be	able	to	deliver	pilocarpine	in	doses	of	5	mg	to	10	mg.	Furthermore,	all	
excipients	 and	 taste	 masking	 agents,	 (if	 included),	 must	 be	 compatible	 with	 the	 drug	 and	 the	
administered	product	should	leave	little	or	no	solid	residue	(Slavkova	and	Breitkreutz,	2015).	
	
3.1.1 Orally disintegrating tablets 
ODTs	 are	 dosage	 forms	which	 quickly	 dissolve,	 disintegrate	 or	melt	 inside	 a	 patient’s	mouth	without	
chewing	and	water	intake	(Moqbel	et	al.,	2016).	They	have	the	advantages	of	ease	of	transportation	and	
swallowing,	accurate	dosing,	rapid	onset	of	action	and	avoidance	of	the	first	pass	effect	(Dhagla	et	al.,	
2012).	According	to	Fu	Y	et	al.,	(2004)	and	Irfan	et	al.,	(2016),	fast	disintegrating	systems	should	dissolve	
in	 a	 small	 amount	 of	 saliva	within	 the	maximum	of	 3	minutes.	 Currently,	 the	 accepted	 disintegrating	
times	 for	ODTs	 range	between	2	and	30	seconds,	e.g.	Xilopar	Zydis®	 and	Calpol®fastmeltsFlashtab® 
(Pabari	 et	 al.,	 2012).	 The	 pharmacopoeia	 guidelines	 provide	 only	 partial	 guidance	 on	 the	 acceptable	
limits	 for	 the	 disintegration	 times	 of	 ODTs	 and	 these	 times	 are	 typically	 measured	 using	 technology	
design	 for	more	 traditional	oral	dosage	 forms	 (Food	and	Drug	Adminstration,	2008).	 	 In	 the	 case	of	 a	
new	 product	 designed	 for	 the	 delivery	 of	 cholinergic	 agents,	 salivary	 stimulation	 will	 be	 directly	
influenced	by	the	disintegration	time	of	the	ODT	product.	Disintegration	time	will	depend	on	the	tablet’s	
dimensions,	 weight,	 manufacturing	 technology	 and	 the	 method	 used	 to	 measure	 disintegration.	
Considering	 all	 of	 the	 possible	 influences,	 salivary	 stimulation	 in	 patients	 diagnosed	 with	 radiation-
induced	xerostomia	should	be	as	fast	as	possible,	thus	a	rapid	disintegration	time	is	required	and	so	a	
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target	 of	 90%	 tablet	 disintegration	 within	 10s	 should	 viewed	 as	 acceptable.	 Thus,	 pilocarpine	 ODT	
formulations	should	ideally	include	an	amorphous	hydrophilic	polymer,	such	as	gelatine	or	alginate	that	
provides	good	wettability	the	required	viscosity	post-disintegration	to	maintain	the	drug	on	the	mucus	
layer	in	addition	to	the	structural	strength	of	the	manufactured	tablet.	Saccharides	may	also	be	included	
to	provide	the	tablets	with	elegance	and	hardness;	such	sugars	include	mannitol	and	sorbitol.	Mannitol	
especially	 conveys	 fast	 disintegration/dissolution	 when	 in	 the	 presence	 of	 small	 amount	 of	 aqueous	
media.	Addition	of	saccharides	also	induces	a	more	uniform	pore	size	in	ODTs	prepared	by	freeze	drying.		
A	 network	 of	 pores	 throughout	 the	 tablet	 allows	 the	 rapid	 water	 uptake.	 Sweeteners,	 pH	 adjusting	
substances	and	preservatives	can	also	be	included	in	ODTs	formulations	if	required	(Sastry	et	al.,	2000).	
	
A	 wide	 range	 of	 approaches	 and	 technologies	 are	 used	 to	 produce	 ODTs	with	 the	 primary	 goal	 of	 a	
balance	 between	 short	 disintegrating	 time	 and	 good	mechanical	 strength.	 Tensile	 strengths	 for	ODTs	
have	been	recorded	between	5	and	nearly	30	N/cm2	(Pabari	et	al.,	2012).	The	most	common	methods	
for	the	manufacture	of	ODTs	are	freeze-drying,	moulding	and	compression.	Freeze-drying	methods	have	
the	advantages	of	producing	tablets	that	disintegrate	rapidly,	2	to	10	s	,	but	also	are	easily	handled	and	
administrated	(Fu	Y	et	al.,	2004).	High	cost	and	length	of	processing	are	the	main	limitations	for	freeze-
drying.	However,	the	preparation	of	the	feed	solution	to	be	freeze-dried	is	relatively	straight	forward	as	
long	 as	 the	 API	 underdevelopment	 has	 a	 high	 enough	 water	 solubility.	 Pilocarpine	 HCl	 fulfils	 these	
criteria,	 as	 it	 possesses	 an	 aqueous	 solubility	 of	 over	 100	 mg/mL	 at	 room	 temperature.	 The	 opioid	
antagonist	naloxone	has	recently	been	reformulated	into	a	freeze-dried	buccal	tablet	formed	by	freeze-
drying.	Mixtures	of	gelatin,	mannitol	and	sodium	bicarbonate	were	used	to	achieve	disintegration	times	
in	less	than	10	seconds.	The	relatively	large	fraction	of	gelatin,	65%	w/w,	did	not	appear	to	inhibit	fast	
delivery,	 but	 it	 did	 lead	 to	 a	 viscous	 solution	 or	 gel	 upon	 disintegration,	 that	 was	 designed	 to	 keep	
naloxone	in	contact	with	the	buccal	mucosa	and	prevent	it	being	swallowed	by	the	patient,	(Alqurshi	et	
al.,	2016).	The	use	of	gelatin	and	other	potential	gelling	agents	 in	combination	with	 freeze-drying	 is	a	
strategy	that	may	permit	both	rapid	disintegration	and	localised	delivery	of	salivary	stimulants.	
	
Instead	of	beginning	with	an	aqueous	based	solution,	moulding	and	compression	approaches	start	with	
the	API	and	excipients	mixed	together	as	solid	powders.	Pressure	 is	applied	to	these	mixtures	to	form	
the	 desired	 product.	 However,	 the	 resulting	 tablets	 tend	 to	 be	 quite	 brittle,	 thus	 moulding	 and	
compression	manufacturing	methods	 increase	 the	 chance	 of	 breakage	 of	 the	 tablets	 during	 handling	
when	 the	 blister	 packaging	 is	 opened	 (Badgujar	 and	 Mundada,	 2011).	 Compression	 methods	 are	
commonly	used	in	pharmaceutical	 industry	due	to	the	low	costs	of	production.	However,	compression	
procedures	 are	 not	 designed	 to	 meet	 the	 specifications	 for	 fast	 disintegrating	 tablets,	 such	 as	 a	
sufficiently	high	porosity	of	20%	or	above,	which	is	crucial	for	rapid	disintegration	(Koseki	et	al.,	2009).		
	
The	 inclusion	 of	 super	 disintegrants,	 for	 example,	 sodium	 starch	 glycolate,	 can	 improve	 the	
disintegration	 times	 for	 the	 relatively	hard	 tablets	produced	by	 compression.	 For	 example,	Nurofen®	
Meltlets	produced	by	dry	granulation	and	compression,	containing	200mg	of	ibuprofen,	disintegrate	in	
just	 over	 30	 seconds,	 whereas	 lyophilised	 (freeze-dried)	 Zofran	 Zydis®	 ODTs	 with	 an	 8	 mg	 dose	 of	
ondansetron	disintegrates	in	just	over	2	seconds,	(Pabari	et	al.,	2012).	
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3.1.2 Orally disintegrating f i lms  
ODFs	are	dosage	forms	which	also	quickly	dissolve,	disintegrate	or	melt	inside	a	patient’s	mouth	without	
chewing	and	water	 intake	 (Moqbel	et	al.,	2016).	A	typical	ODF	formulation	contains	 in	addition	to	the	
active	 pharmaceutical	 ingredient,	 a	 hydrophilic	 polymer,	 a	 plasticiser,	 a	 filler	 and	 a	 flavouring	 agent	
(Keshari	 et	 al.,	 2014).	 	 ODFs	 may	 contain	 synthetic	 and	 the	 natural	 polymers	 which	 are	 required	 to	
provide	the	ODF	with	excellent	spreadability	and	good	mechanical	strength,	(table	5).		
	
Table	5:	Examples	of	natural	and	synthetic	polymers	used	in	ODFs		(Dhagla	R.	et	al.,	2012).	
Natural	polymers		 Synthetic	polymers	
Starch	 Methyl	cellulose	
Polymerised	rosin	 Hydroxypropyl	cellulose	
Sodium	alginate	 Pyrrolidone	
Gelatin	 	
	
Casting	 (solvent	 and	 semi-solid	 casting),	 extrusion	 (hot	 melt	 and	 solid	 dispersion)	 and	 rolling	 are	
methods	 for	 manufacturing	 ODFs.	 Solvent	 casting	 is	 the	 most	 commonly	 used	 method	 as	 it	 is	
straightforward	 and	 easy.	 However,	 ODFs	 prepared	 by	 the	 solvent	 casting	 method	 have	 the	
disadvantages	 of	 limited	 production	 capacity,	 environmental	 concerns,	 and	 instability	 generated	 by	
unpredictable	 factors	 such	 as	 polymer	 chain	 relaxation,	 moisture	 absorption	 or	 loss,	 and	 polymer-
plasticizer	 interaction	during	storage	 (Low	et	al.,	2013).	Hot-melt	extrusion	has	 the	advantage	of	both	
simplicity	 and	 high	 production	 capacity	 and	 is	 often	 used	 to	 enhance	 the	 solubility	 of	 poorly	 soluble	
active	 ingredients	 (Bala	et	al.,	2013).	The	complexity	of	equipment,	elevated	processing	 temperatures	
and	high	development	costs	are	the	main	disadvantages	of	this	method	(Low	et	al.,	2013).	Finally,	the	
rolling	process	is	also	one	of	the	standard	methods	used	to	produce	a	uniform	formulation	matrix	and	a	
controllable	thickness	of	film	by	the	use	of	an	applicator	roller	(Nagaraju	et	al.,	2013).	 	Pilocarpine	has	
been	 fabricated	 as	 a	 sublingual	 film	 and	 proven	 effective	 for	 the	 treatment	 of	 Sjögren’s	 syndrome	
(Rodríguez-Pulido	et	al.,	2017),	but	has	not	been	evaluated	in	radiation-induced	xerostomia.	
	
3.1.3 Medicated chewing gum 
Medicated	chewing	gum	is	a	drug	delivery	system	containing	a	masticatory	gum	base	with	one	or	more	
pharmacologically	active	substances	that	can	be	released	after	a	short	time	of	mastication	(Aslani	and	
Rostami,	2015).	Chewing	gum	delivery	systems	have	a	broad	range	of	advantages	and	few	side	effects.	
The	 active	 ingredient	 can	 be	 delivered	 to	 induce	 either	 local	 or	 systemic	 effect,	 fast	 onset	 of	 action,	
superior	 taste	and	ease	of	administration	without	a	need	of	water	 (Morjaria	et	al.,	2004;	Pratik	et	al.,	
2011).	Moreover,	medicated	chewing	gum	has	been	successfully	used	to	deliver	a	broad	range	of	active	
ingredients	such	as	nicotine,	dimenhydrinate	,	and	commercial	dental	products	containing	fluoride	and	
carbamide	 (Mehring	 and	Waukesha,	 1997;	 Valoti.	 et	 al.,	 2003).	 Therefore,	 it	 would	 be	 interesting	 to	
reformulate	 pilocarpine	 to	 locally	 activate	 the	minor	 salivary	 glands	 through	 direct	 absorption	 of	 the	
drug	into	the	buccal	mucosal	tissues	from	a	gum	base.		
	
For	 successful	medicated	 chewing	gum,	 the	manufacturing	method	 should	be	able	 to	deliver	5	mg	of	
pilocarpine	without	the	need	of	water	and	with	a	pleasant	mouth	feel.	The	manufactured	chewing	gum	
should	be	stable	 towards	humidity	and	 temperature	changes.	Water	 soluble	and	water-insoluble	gum	
bases	 are	 the	 typical	 composition	 of	 a	 medicated	 chewing	 gum,	 (table	 6).	 There	 are	 two	 types	 of	
manufacturing	methods	 available	 for	manufacturing	medicated	 chewing	 gums	namely,	 the	 traditional	
method	 based	 on	melting	 and	 a	more	 recent	 direct	 compression	 approach	 (Maggi	 et	 al.,	 2005).	 The	
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direct	compression	method	has	advantages	of	high	 loading	capacity,	chemical	stability	and	faster	drug	
release	(Maggi	et	al.,	2005).	
	
The	drug	release	times	from	of	medicated	chewing	gum	are	not	specified	by	any	pharmacopoeia	as	it	is	
affected	 by	 many	 different	 factors.	 For	 example,	 the	 aqueous	 solubility	 of	 the	 drug	 influences	 the	
release	rate,	as	the	gum	must	be	hydrated	by	saliva	for	the	drug	to	dissolve	and	then	diffuse	through	the	
action	 of	 chewing	 (Maggi	 et	 al.,	 2005).	 Moreover,	 the	 drug	 release	 from	 the	 chewing	 gum	 is	 also	
controlled	by	the	contact	time,	chewing	time,	intensity	and	rate,	which	can	vary	between	patients.	The	
European	Pharmacopeia	suggested	that	60	chews/min	is	the	average	rate	to	release	an	active	ingredient	
from	 a	 gum	 (Pharmacopia,	 2005).	 More	 generally,	 patients	 with	 dry	 mouth	 may	 struggle	 to	 use	 a	
chewing	gum,	with	the	crushing	of	the	gum’s	initially	un-wetted	and	hard	structure	causing	difficulties.	
The	absence	of	normal	salivary	 flow	and	 limited	 lubrication	for	this	process	will	 result	 in	poor	sensory	
mouthfeel.	
	
	
Table	 6:	 Typical	 component	 of	 medicated	 chewing	 gum	 along	 with	 their	 formulation	 percentage,	 functions	 and	 examples	
(Aslani	and	Rostami,	2015).	
Typical	components	of	medicated	chewing	gum	
Water	soluble	components	
Component	 Proportion	by	
weigh	
Function		 Examples	
Sugar	
sweeteners	
30-60%	 Taste	improvement.	 Sucrose,	dextrose,	maltose,	
fructose.	
Softener	
(plasticizers)	
0.5-15%	 Texture	modification.	 Glycerin,	lecithin,	sorbitol.	
Emulsifier	 15-45%	 Facilitate	the	dispersion	of	two	
immiscible	products.	
Stearyl	acetate,	lactylic	
esters.	
Water	Insoluble	gum	base	
Elastomers	 15-45%	 Provide	gum	with	rubbery	texture.	 Polyisobutylene,	
isobutylene.	
Rubber	 15%	 Softener	and	binding	agent.	 Glycerol	esters,	terpene	
resins.	
Filler	 50%	 Texture	modifiers.	 Magnesium	and	calcium	
carbonate.	
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3.1.4 Implantable drug delivery devices 
Another	pharmaceutical	solution	is	to	build	an	oral	device	and	implant	this	into	a	prosthetic	tooth	crown	
or	embed	inside	a	denture.	All	implantables	aim	to	reduce	the	frequency	of	drug	administration,	and	in	
doing	 so	 such	 devices	 permit	 site-specific	 drug	 administration	 and	 continual	 release	 of	 a	 therapeutic	
agent	(Scholz	et	al.,	2008).	Drug	release	from	implantable	drug	delivery	systems	may	achieve	both	local	
and	 prolonged	 drug	 release.	 Thus	 controlled	 release	 implants	 enhance	 the	 efficacy	 of	 the	 therapy,	
decrease	 dose-related	 side	 effects	 and	 thus	 improve	 patient’s	 adherence	 because	 the	 administrated	
active	ingredient	can	in	some	cases	be	individually	adjusted	(Scholz	et	al.,	2008).	
	
Implantable	drug	delivery	devices	must	meet	the	following	specific	requirements	to	be	successful:	The	
device	 should	 be	 biocompatible;	 it	 must	 be	 stable	 and	 withstand	 the	 harsh	 environment	 inside	 the	
mouth,	 such	 as	 high	 humidity,	 temperature	 variations,	 the	 force	 of	 mastication	 and	 salivary	 buffers.	
Additionally,	ease	of	manufacturing	and	relatively	low	product	costs	are	important.		
	
Implantable	 drug	 delivery	 technologies	 may	 be	 divided	 into	 non-degradable	 and	 degradable	 implant	
systems	 (Rajgor	 et	 al.,	 2011).	 The	 non-degradable	 systems	 include	 polymeric	 matrices	 reservoir-type	
devices	and	magnetically	controlled	platforms.	The	biodegradable	systems	have	the	advantage	of	using	
inert	 polymers	 that	 are	 eventually	 absorbed	 by	 the	 body.	 Thus,	 the	 design	 and	 development	 of	 such	
systems	are	more	complicated	 in	comparison	to	the	non-biodegradable	systems.	Designing	a	reservoir	
containing	 pilocarpine	 and	 implanting	 this	 into	 a	 prosthetic	 tooth	 crown	 or	 inside	 a	 denture	 is	 an	
efficient	way	for	the	drug	to	be	in	close	contact	with	the	buccal	mucosa	but	as	yet	no	suitable	prototype	
exists.	
	
										Implantable	 systems	may	also	 contain	 small	electrodes	 that	 function	 to	 stimulate	 salivary	 flow.	Smidt	
and	Andy,	 2010	 evaluated	 the	 efficacy	 of	 an	 electro-stimulation	device	 as	 a	 fixed	 implant	 for	 salivary	
secretion.	The	main	purpose	of	their	approach	was	to	stimulate	the	secretion	of	natural	saliva	over	an	
extended	period	using	the	implanted	electrodes.	This	was	accomplished	by	electrical	stimulation	of	the	
long	 buccal	 nerve	 and	 lingual	 nerve,	 through	 an	 artificial	 dental	 implant.	 The	 price	 of	 such	 devices	 is	
expected	 to	 be	 high	 and	 thus	will	 not	 be	 an	 option	 for	 all	 patients.	 Furthermore,	 this	 class	 of	 device	
requires	 regular	maintenance	as	 it	 contains	a	battery	 that	needs	 to	be	 replaced,	microprocessors	and	
sensors	which	all	require	removal	of	the	implant	if	they	fail.	
4 Patient	centric	pharmaceutical	drug	product	design		
Consideration	 of	 the	 patient-medicine	 interface	 is	 essential	 during	 the	 design	 of	 any	 pharmaceutical	
formulation	where	 the	patient’s	needs	are	at	 the	 core	of	 the	design.	 Therefore,	 improvements	 in	 the	
delivery	of	salivary	stimulants	must	be	designed	based	on	the	information	available	regarding	the	needs	
of	 patients	 with	 radiation-induced	 xerostomia.	 From	 a	 patient	 perspective,	 xerostomia	 can	 make	
swallowing	conventional	tablets	difficult	which	may	lead	to	choking	(Kaur	et	al.,	2011).		A	topical	buccal	
therapy	would	avoid	the	need	to	swallow	a	tablet.	
	
Orally	disintegrating	formulations,	medicated	chewing	gums	and	implantable	drug	delivery	devices	have	
many	advantages	over	the	conventional	pilocarpine	HCl	tablets	(table	7).	However,	the	implantable	drug	
delivery	 devices	 are	 expensive	 and	 poorly	 responsive	 to	 a	 sudden	 change	 in	 the	 patient’s	 needs	 for	
example	when	eating	a	meal.	In	addition,	most	of	the	patients	with	radiation-induced	xerostomia	have	
dental	decay	and	mucosal	sensitivity	(Murphy	et	al.,	2007).	Therefore,	attaching	an	 implant	within	the	
mouth	may	be	problematic	 as	 decay	 leads	 to	 an	unstable	dental	 architecture	 and	patients’	 increased	
sensitivity	 to	 foreign	objects	will	 reduce	adherence.	For	medicated	chewing	gum,	 saliva	 is	 required	 to	
initiate	the	chewing	process,	and	this	 is	 impossible	 for	patients	with	severe	xerostomia.	 In	addition	to	
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this,	the	age	of	patients	diagnosed	with	head	and	neck	cancer	fall	within	the	range	of	60	to	69	years	old	
when	tooth	loss	is	highly	possible	making	extended	chewing	difficult	(Liu	et	al.,	2016).	
	
Table	 7:	 Shows	 the	 recommended	 pharmaceutical	 dosage	 forms	 and	 their	 attributes	 to	 improve	 the	 efficacy	 and	 patient’s	
compliance	for	the	conventional	pilocarpine	HCl	tablets.	
	
Among	the	limitations	of	all	dosage	forms	that	are	designed	to	release	their	drug	in	the	oral	cavity	is	the	
possibility	 that	 the	patients	may	accidentally	 swallow	 these	medicines	before	 they	are	 fully	dispersed	
and	 the	 drug	 is	 released.	 However,	 this	 issue	 may	 be	 addressed	 by	 achieving	 extremely	 rapid	
disintegration	of	the	formulation	or	using	specific	excipients	to	keep	the	drug	located	on	the	surface	of	
the	buccal	mucosa.	Orally	disintegrated	tablets	quickly	disintegrate	with	minimal	effort	and	without	the	
need	 of	 water,	 therefore,	 this	 dosage	 form	 perfectly	 suits	 elderly	 patients	 diagnosed	 with	 radiation-
induced	xerostomia	where	dysphagia	 is	one	of	 the	most	common	symptoms	of	 the	condition.	A	study	
conducted	 by	 Liu	 et	 al.,	 (2016)	 found	 that	 elderly	 people	 with	 dysphagia	 prefer	 orally	 disintegrating	
tablets	 over	 other	 pharmaceutical	 dosage	 forms	 such	 as	 chewing	 gums,	 mini	 tablets	 and	 dispersible	
tablets.	Therefore,	delivering	the	pilocarpine	using	an	orally	disintegrating	tablet	would	be	expected	to	
enhance	patient’s	adherence	to	the	medicine.	To	achieve	a	patient	centric	design,	an	ODT	used	for	the	
treatment	 of	 xerostomia	must	 be	 optimised	 for	 shape	 and	 size.	 These	 parameters	 should	match	 the	
dimensions	of	the	finger	print	area	of	the	thumb	in	order	to	ease	administration	and	attachment	to	the	
buccal	 area.	 In	 addition,	 patients	 with	 radiation-induced	 xerostomia	 might	 require	 a	 range	 of	
therapeutic	 doses	 based	 on	 the	 severity	 of	 dry	 mouth.	 Freeze	 drying	 plays	 a	 central	 role	 in	 the	
development	of	orally	disintegrating	tablets	whereby	the	dose	may	be	easily	adjusted	within	a	known	
design	 space,	 to	 meet	 patient’s	 needs	 by	 titrating	 different	 amounts	 of	 the	 active	 ingredient.	 Many	
drugs	 have	 a	 bitter	 taste	 so	 taste-masking	 technologies	 are	 often	 required	 in	 ODTs.	 This	 may	 be	
achieved	by	the	addition	of	taste	masking	excipients	to	the	solution	prior	to	freeze	drying,	but	only	after	
compatibility	with	the	API	has	been	confirmed.		
	
	
	 	
Recommended	 dosage	
forms		
Attributes	
	
Loading	
capacity	
Fast	delivery	
(90	 %	 of	 the	
drug	
disintegrated	
within	10s)	
	
Administered	 with	
little	or	no	water	
	
Local	
delivery	
	
Economic	
Oral	disintegrating	
tablets	
ü 	 ü 	
	
ü 	 ü 	 ü 	
Chewing	gum	 ü 	 X	
	
X	
	
ü 	 ü 	
Implantable	drug	
delivery	devices	
ü 	 X ü 	 ü 	 X	
Conventional	
pilocarpine	HCl	tablets	
ü 	 							X	 								X	 								X	 ü 	
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5 Conclusion	&	Recommendations	
Xerostomia	 is	 common	 in	 head	 and	 neck	 cancer	 patients	 treated	 with	 radiotherapy.	 If	 untreated,	
xerostomia	 can	 cause	 complications	 including	 nutritional	 deficiencies,	 low	mood	 and	 depression.	 The	
current	 treatments	 for	 radiation-induced	 xerostomia	 are	 suboptimal.	 Pilocarpine,	 the	 only	
pharmacophore	 licensed	 to	 treat	 this	 condition,	 is	 beset	 by	 off-target	 side	 effects	 associated	 with	
cholinergic	 therapy.	 Local	 application	 to	 the	 buccal	 mucosa	 would	 have	 the	 advantages	 of	 ease	 of	
administration,	good	bioavailability	and	fast	onset	of	action.		Therefore,	reformulation	of	pilocarpine,	or	
other	 salivary	 stimulants,	 as	 a	 buccal	 formulation	 would	 be	 a	 significant	 step	 in	 improved	
pharmacotherapy	 of	 radiation-induced	 xerostomia.	 Fast	 disintegrating	 buccal	 tablets	 containing	
pilocarpine	 could	meet	 the	 needs	 of	 patients	with	 radiation-induced	 xerostomia	 including	 those	with	
dysphagia	 or	 benefitting	 from	 dose	 titration.	 Patient-centred	 pharmaceutical	 development	 would	
ensure	that	the	technology	is	designed	to	address	both	the	therapeutic	needs	and	the	lifestyle	of	those	
suffering	 xerostomia.	 Fragmented	 knowledge	 and	 uncertainties	 regarding	 target	 criteria	 for	 product	
performance	can	be	addressed	by	engagement	with	patients	and	expert	practitioners.		Such	information	
would	help	establish	a	design	specification	so	that	product	attributes	that	reflect	patient	needs	can	be	
defined	for	orally	dispersible	pilocarpine	HCl	tablets.		
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